| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.31 | 8e-08 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | -0.21 | 8e-08 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.22 | 8e-08 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.2 | 1e-07 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-07 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.19 | 3e-07 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | -0.2 | 3e-07 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.19 | 5e-07 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.19 | 6e-07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-06 |